This article will summarise the results of clinical research studies conducted by the company, "Taheebo Japan Co., Ltd." located in Osaka, Japan. Clinical laboratory tests were conducted at Tokyo University and other profession medical laboratories which culminated in the issuance of United States Patent Number 5,663,197 on September 2, 1997.
Taheebo Japan then produced and marketed a substance called "NFD" which they marketed as a tea product and priced the product at $280.00(US) per pound.
This patent proves that constituents extracted from the Tabebuia Avellanedae (Pau d'Arco) tree bark "remarkably inhibits the growth" and "exhibits selective toxicity" of 23 specific types of cancer cells. The compound also "was found to inhibit the growth almost completely" and "cause necrosis (death)" in 12 specific types of malignant cancer tumors.
Here are the 23 different types of cancer cells listed in the study:
- Human Lung Adenocarcinoma A-549 Cells
- Human Lung Adenocarcinoma VMRC-LCD
- Human Lung Adenocarcinoma SK-LU-1
- Human Lung Squamous Carcinoma
- Human Colon Adenocarcinoma WiDr
- Human Prostate Cancer LNCaP
- Human Squamous Cell Carcinoma A-431
- Human Cervical Carcinoma HeLa
- Human Cholangiocarcinoma HuCC-T1
- Mouse Melanima B16 (M4)
- Human Malignant B-Cell Lymphoma
- Human Chronic Myelogenous Leukemia K-562
- Human Pancreatic Carcinoma ASPC-1
- Human Neuroblastoma IMR-132
- Human Urinary Bladder Carcinoma T24
- Human Renal Cell Carcinoma VMRC-RCW
- Human Gastric Cancer NUGC-2
- Human Thyroid Carcinoma 8305C
- Human Breast Cancer MRK-nu-1
- Human Hepatoma HUH-7
- Human Ovarian Carcinoma TYK-nu
- Human Chorio Carcinoma BeWo
Here are the 12 different types of malignant tumors listed:
- Human Lung Anenocarcinoma
- Human Colon Anenocarcinoma
- Squamous Cell Carcinoma
- Cervical Carcinoma
- Pancreatic Carcinoma
- Lung Carcinoma
- Bladder Carcinoma
- Renal Cell Carcinoma
- Thyroid Carcinoma
- Cholangiocarcinoma
- Ovarian Carcinoma
- Chorio Carcinoma
This patent was approved and obtained on the results of scientific laboratory research studies. This study does not make any claims as to the results that may be attained when using the "NFD" product as a herbal remedy for cancer. Human research studies have not been done to date. Why haven't human research studies on such a promising herbal remedy been accomplished? We can only speculate...
Also, this study used only three of the constituents from the Pau d'Arco tree bark. There are over 20 different identified constituents that reside in this remarkable herb. As stated in Walter Lubeck's book, "The Healing Power of Pau d'Arco", "There wasn't just one individual "miracle active ingredient" in Pau D'Arco responsible for all the good results. Its extensive healing power originates in the totality of the substances contained within this plant, which we are completely justified in calling unique, and their fortunate balanced state and harmonious combination with each other. Because of the fantastic composition of the active ingredients, even the smallest amounts of the individual active ingredients can make a decisive contribution to processes like the inhibition of tumor growth. If the components are used in an isolated manner, much of their healing power disappears and the excellent tolerance and harmonious effect of the tea is often lost.
Medical experts speculate with me that Pau d'Arco tea, in its natural state, is more effective than any form of a "processed" product.
Click here to view U. S. Patent No. 5,663,197